poisar

Stocks · News reference

Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis

Aug 14, 2026, 11:05 AMBenzinga Newsdesk

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated regulatory pathway

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FATE
Source
benzinga
Observed
Aug 14, 2026, 11:05 AM
Checked
Aug 14, 2026, 11:05 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading